Bio­gen spells out re­mark­able ef­fi­ca­cy da­ta in Alzheimer's for ad­u­canum­ab, but safe­ty threat per­sists

Saman­tha Budd Hae­ber­lein, Bio­gen

Shares of Bio­gen jumped Thurs­day af­ter­noon af­ter an up­dat­ed as­sess­ment of the re­mark­ably pos­i­tive da­ta they’ve been col­lect­ing from the PRIME study of their Alzheimer’s drug hope­ful ad­u­canum­ab was leaked among in­vestors and then quick­ly spread on­line.

Aside from the ker­fuf­fle over how the da­ta first be­gan to sur­face, a close look at the full set of re­sults re­vealed a sur­pris­ing­ly pos­i­tive read­out that will help ig­nite re­newed en­thu­si­asm for Bio­gen’s prospects in what is per­haps the tough­est field in R&D — though a big safe­ty is­sue re­mains a key con­cern.

Look­ing over the da­ta from 196 pa­tients, in­ves­ti­ga­tors re­port­ed that they tracked sig­nif­i­cant de­creas­es in amy­loid plaque bur­den in the brains of pa­tients tak­ing a titrat­ed 10 mg dose of the drug “dur­ing 12 months of treat­ment in ApoE ε4-pos­i­tive pa­tients with pro­dro­mal or mild AD com­pared with place­bo.” And they linked that to a clear and sig­nif­i­cant slow­ing of the dis­ease.

Bio­gen’s shares end­ed up 1.5% at the close, af­ter bounc­ing up and down as the da­ta were passed around. In pre-mar­ket trad­ing shares spiked 3.75%.

In­ves­ti­ga­tors were able to track a slow­ing in the de­cline among pa­tients tak­ing a titrat­ed dose of ad­u­canum­ab. And the most com­mon ad­verse ef­fect, ARIA, “ap­peared” to be re­duced among the titrat­ed drug arm com­pared to the high­er fixed dose among pa­tients with the ApoE4 gene, which may pre­dis­pose them to the dis­ease.

The slow­ing in the Clin­i­cal De­men­tia Rat­ing-Sum of Box­es (CDR-SB, which mea­sures cog­ni­tive and func­tion­al per­for­mance) scale was sta­tis­ti­cal­ly sig­nif­i­cant in the titrat­ed arm com­pared to the place­bo group. And the in­ves­ti­ga­tors say they felt the da­ta they had gath­ered sup­port­ed the de­sign of their Phase III study, which puts this drug to the piv­otal test.

There ap­peared to be a clear dose re­sponse to the drug, which is what in­ves­ti­ga­tors like to see.

In a re­lease is­sued late Thurs­day, Bio­gen spelled out the changes in both the CDR-SB and MMSE mea­sures, break­ing out the scores by dos­es com­pared to a place­bo. For the CDR-SB Group, the place­bo arm wors­ened by an av­er­age of 1.89 points at 54 points. That was close to the 1.69 point drop for the 1 mg group, but far worse than the 0.70 in the titra­tion arm. The 10 mg group had the best score of 0.63.

On the MMSE score, the place­bo arm wors­ened an av­er­age of 2.45 points, but that dropped to 0.55 in the 10 mg arm and 1.00 in the titra­tion arm.

ARIA, though, is clear­ly a per­sis­tent prob­lem. The in­ci­dence of ARIA-E in ApoE4 car­ri­ers in the fixed-dose arms was 5 per­cent in the 1 mg/kg and 3 mg/kg arms, 43 per­cent in the 6 mg/kg arm and 55 per­cent in the 10 mg/kg arm. The in­ci­dence of ARIA-E in ApoE4 car­ri­ers in the titra­tion arm was 35 per­cent.

Bri­an Sko­r­ney, Baird an­a­lyst

This is some of the most en­cour­ag­ing da­ta the Alzheimer’s field has seen in years, leav­ing ad­u­canum­ab as one of the top prospects now in late-stage de­vel­op­ment. While much more safe­ty and ef­fi­ca­cy da­ta re­main to be gath­ered in piv­otal stud­ies, its suc­cess at this stage marks a po­ten­tial turn­ing point, which could be rich­ly re­ward­ed by a mar­ket des­per­ate for an ef­fec­tive ther­a­py, es­pe­cial­ly so soon af­ter Eli Lily’s so­la flopped.

“Both ab­stracts high­light sig­nif­i­cant de­clines in plaque bur­den and as­so­ci­at­ed ben­e­fits in terms of the rate of clin­i­cal de­cline, with the titra­tion co­hort show­ing a stat sig ben­e­fit on CDR-SB com­pared to place­bo at 12 months,” not­ed Bri­an Sko­r­ney, who was en­cour­aged by the ex­ten­sion da­ta. He added:

 Of the 165/196 pa­tients in the PRIME study on a fixed dose, 91 were evalu­able out to 24 months. Pa­tients switched from place­bo to ad­u­canum­ab did show de­clines in plaque bur­den and slow­er rates of cog­ni­tive/func­tion­al de­cline. Pa­tients in the 10mg/kg and 6mg/kg dose groups re­main­ing on drug saw con­tin­ued ben­e­fit out to 24 months and an even more sig­nif­i­cant re­sponse than those who were switched on­to drug af­ter place­bo. There were no new cas­es of ARIA for those con­tin­u­ing on ad­u­canum­ab in the LTE. The one year fol­low up should be in­ter­pret­ed with cau­tion as pa­tients know they are on treat­ment and the clin­i­cal mea­sure­ments are sub­ject to high vari­abil­i­ty.

Ad­u­canum­ab is a crit­i­cal­ly im­por­tant drug for Bio­gen, which has ex­pe­ri­enced a se­ries of pipeline ups and downs as its block­buster Tec­fidera has be­gun to wane on the big mul­ti­ple scle­ro­sis mar­ket.

“The da­ta at CTAD sup­port the pos­i­tive re­sults we have seen in our Phase 1b study of ad­u­canum­ab, and they pro­vide in­sight in­to the ob­served ef­fects in pa­tients treat­ed for up to two years,” said Saman­tha Budd Hae­ber­lein, vice pres­i­dent, clin­i­cal de­vel­op­ment at Bio­gen. “We are com­mit­ted to ad­vanc­ing our glob­al Phase 3 pro­gram for ad­u­canum­ab as well as the sci­en­tif­ic un­der­stand­ing of Alzheimer’s dis­ease so we can help iden­ti­fy a treat­ment for the many peo­ple af­fect­ed by this ter­ri­ble dis­ease.”

https://twit­ter.com/Arm­strong­Drew/sta­tus/806952994855997440

Illustration: Assistant Editor Kathy Wong for Endpoints News

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

Don Kyle spent more than 20 years working for Purdue Pharma, right through the US opioid epidemic that led to the company’s rise and eventual infamy. But contrary to Purdue’s focus on OxyContin, Kyle was researching non-opioid painkillers — that is, until the company shelved his research.

As the company’s legal troubles mounted, Kyle found an unlikely way to reboot the project. In 2019, he took his work to an Oklahoma State University center that’s slated to receive more than two-thirds of the state’s $272 million settlement with Purdue over claims that the drugmaker’s behavior ignited the epidemic of opioid use and abuse.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

President Joe Biden at the State of the Union address with Vice President Kamala Harris and House Speaker Kevin McCarthy (Patrick Semansky/AP Images)

The drug pric­ing pres­i­dent: Biden warns of ve­to for any IRA re­peal at­tempts

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Rupert Vessey, Bristol Myers Squibb head of research and early development

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search cham­pi­on

This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.

The news arrives amid a turbulent R&D stage for the pharma giant, which late last week highlighted Rupert Vessey’s decision to depart this summer as head of early-stage R&D following a crucial three-year stretch after he jumped to Bristol Myers in the big Celgene buyout. During that time he struck a series of deals for Bristol Myers, and also shepherded a number of Celgene programs down the pipeline, playing a major role for a lineup of biotechs which depended on him to champion their drugs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Utpal Koppikar, new Verily CFO

Ex­clu­sive: Ver­i­ly wel­comes Atara Bio­ther­a­peu­tics vet­er­an as new CFO

Verily, Alphabet’s life sciences outfit, has plucked a new CFO from the ranks of Atara Biotherapeutics, the company announced on Wednesday.

Utpal Koppikar joins Verily after a nearly five-year stint as CFO and senior VP at Atara, though his résumé also boasts roles at Gilead and Amgen.

The news follows a major reshuffling at Verily, including several senior departures earlier this year and a round of layoffs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It didn’t measure up on clinical performance.

But Bill Haney, the CEO of Dragonfly, is taking issue with that.

The early-stage drug, still in Phase I development, has passed muster with Bristol Myers’ general clinical expectations, advancing successfully while still in Phase I, he says.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Singer Nick Jonas is back at work for Dexcom, this time for its new G7 glucose monitor.

Dex­com's spokescelebri­ty Nick Jonas re­turns to Su­per Bowl in new glu­cose mon­i­tor com­mer­cial

Dexcom is going back to the Super Bowl with its pop singer and patient spokesperson Nick Jonas. Jonas takes center stage as the lone figure in the 30-second commercial showcasing Dexcom’s next-generation G7 continuous glucose monitoring (CGM) device.

Jonas’ sleight-of-hand tricks populate the commercial — he pinches his empty fingers together and pops them open to reveal the small CGM — even as he ends the ad, saying, “It’s not magic. It just feels that way.” Jonas then disappears in a puff of smoke.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Richard Francis, newly-appointed Teva CEO (Novartis via Facebook)

New Te­va CEO Richard Fran­cis repri­or­i­tizes to 'get back to growth'

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

FDA Commissioner Robert Califf on Capitol Hill, Feb. 8, 2023 (Drew Angerer/Getty Images)

FDA com­mis­sion­er floats ideas on how to bet­ter han­dle the pan­dem­ic

FDA Commissioner Rob Califf joined the heads of the CDC and NIH in the hot seat today before a key House subcommittee, explaining that there needs to be a much faster, more coordinated way to oversee vaccine safety, and that foreign biopharma inspections, halted for years due to the pandemic, are slowly ramping up again.

Califf, who stressed to the House Energy and Commerce’s Subcommittee on Health that the CDC also needs better data, made clear that the FDA’s ability to monitor the safety of vaccines “would also benefit greatly by a coordinated federal public health data reporting authority.”

Sanofi is renewing its #VaccinesForDreams campaign with more stories, such as Juan's in Argentina (Sanofi)

Sanofi re­news so­cial cam­paign to re­mind that vac­cines let peo­ple ‘Dream Big’

Sanofi is highlighting people’s dreams — both big and small — to make the point that vaccines make them possible.

The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teacher in the Misiones rainforest in Argentina whose story is told through videos on Instagram and Sanofi’s website with the hashtag #VaccinesForDreams.

The campaign ties to Sanofi’s broader umbrella initiative “Vaccine Stories” to promote the value of vaccines and drive awareness of the need for improved vaccination coverage.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.